Pim2 is important for regulating DNA damage response in multiple myeloma cells

被引:18
|
作者
Ramachandran, J. [1 ]
Santo, L. [1 ]
Siu, K. T. [1 ]
Panaroni, C. [1 ]
Raje, N. [1 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, POB 216,55 Fruit St, Boston, MA 02114 USA
来源
BLOOD CANCER JOURNAL | 2016年 / 6卷
关键词
SERINE/THREONINE KINASE PIM-2; DOXORUBICIN; INHIBITION; RADIATION; SURVIVAL; THERAPY; CANCERS; GROWTH; TUMOR;
D O I
10.1038/bcj.2016.73
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pan proviral integrations of Moloney virus (PIM) inhibition in multiple myeloma (MM) results in reduced cell viability in tested human-derived MM cell lines and reduces tumor burden in xenograft mouse models, making PIMs important therapeutic targets for the disease. PIM kinase inhibitors are currently being tested clinically in MM. We sought to elucidate the role of the various PIMs in MM. Our data demonstrate that Pim2 has a significant role in MM cell cytotoxicity. Our data provide evidence for a novel role for Pim2 in the regulation of the DNA damage response (DDR). Knockdown of Pim2 upregulates several downstream DDR markers, mimicking the effects of doxorubicin (Dox) treatment of MM cells, and suggesting a role for the kinase as a negative regulator of this pathway. Dox-induced DNA damage results in a decrease in Pim2 levels, placing the kinase directly downstream of the site of Dox-DNA binding. Overexpression of Pim2 confers a slight survival advantage against Dox through antiapoptotic activity, further underscoring its relevance in the DDR pathway. These data provide insights into a novel mechanism of PIM kinase activity and provide the framework for designing therapeutic approaches in MM.
引用
收藏
页码:e462 / e462
页数:7
相关论文
共 50 条
  • [41] Mixed galactolipid anomers accentuate apoptosis of multiple myeloma cells by inducing DNA damage
    Deng, Si-Si
    Zhang, Chao
    Wang, Huan
    Zang, Yi
    Li, Jia
    He, Xiao-Peng
    Chen, Guo-Rong
    CARBOHYDRATE RESEARCH, 2015, 408 : 114 - 118
  • [42] Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells
    Ma, Leyuan
    Pak, Magnolia L.
    Ou, Jianhong
    Yu, Jun
    St Louis, Pamela
    Shan, Yi
    Hutchinson, Lloyd
    Li, Shaoguang
    Brehm, Michael A.
    Zhu, Lihua Julie
    Green, Michael R.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (21) : 10482 - 10487
  • [43] Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis. and DNA damage response
    Cai, Bo
    Lyu, Hui
    Huang, Jingcao
    Wang, Shuiliang
    Lee, Choon-Kee
    Gao, Chunji
    Liu, Bolin
    CANCER LETTERS, 2013, 335 (02) : 343 - 350
  • [44] Pim-2 Kinase Regulates Energy Metabolism in Multiple Myeloma
    Liu, Zhaoyun
    Guo, Yixuan
    Liu, Xiaohan
    Cao, Panpan
    Liu, Hui
    Dong, Xifeng
    Ding, Kai
    Fu, Rong
    CANCERS, 2023, 15 (01)
  • [45] DNA2-An Important Player in DNA Damage Response or Just Another DNA Maintenance Protein?
    Pawlowska, Elzbieta
    Szczepanska, Joanna
    Blasiak, Janusz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
  • [46] Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma
    Zhao, Cen
    Yang, Dawei
    Ye, Yuchen
    Chen, Zhenzhong
    Sun, Tifan
    Zhao, Jiawei
    Zhao, Kai
    Lu, Na
    BIOCHEMICAL PHARMACOLOGY, 2021, 190
  • [47] Dysregulation of cyclin D expression in multiple myeloma alters the cell cycle response to DNA damage
    Smith, D. E.
    Yong, K.
    Mann, D. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 49 - 49
  • [48] ANNEXIN A1 AS AN IMPORTANT REGULATOR OF PLACENTAL CELLS RESPONSE TO DNA DAMAGE IN MICE
    Moreli, Jusciele Brogin
    Santos, Mayk Ricardo
    Molas, Rafaela Batista
    Hebeda, Cristina B.
    Farsky, Sandra H. P.
    Oliani, Sonia Maria
    PLACENTA, 2019, 83 : E64 - E64
  • [49] Role for MicroRNAs in Regulating Glucocorticoid Response and Resistance in Multiple Myeloma
    Tessel M.A.
    Benham A.L.
    Krett N.L.
    Rosen S.T.
    Gunaratne P.H.
    Hormones and Cancer, 2011, 2 (3): : 182 - 189
  • [50] AL amyloidosis or multiple myeloma? An important distinction - response to Falk
    Dinner, Shira
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (05) : 749 - 750